medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2008; 55 (4)

Hepatitis C and clinical laboratory

Barba EJB

Language: Spanish
References: 18
Page: 187-200
PDF size: 176.70 Kb.


ABSTRACT

After more than a decade, since the initial description of hepatitis C virus (VHC), a wide range of diagnostic test have been described. In this document available date are presented according on diagnostic test’s reliability and applicability.


REFERENCES

  1. Álvarez MH, Pérez CE. Pruebas diagnósticas para hepatitis C. Med Int Mex 2004; 20: 368-372.

  2. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F Neal KR, Nemo GJ. Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 2000; 31: 756-762.

  3. Vences AMA, González BF. Diagnóstico de la infección por el virus de la hepatitis C en donadores de sangre. Rev Mex Patol Clin 2005; 52 (1): 6-12.

  4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.

  5. Booth JC, O´Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001, 49 (suppl I): I1-I21.

  6. Schulze-Krebs A, Premiel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005; 129: 246-258.

  7. Chapkon MK, Sloan KL, Davison JW, Dufour DR, Bankson DD, Rigsby M, Dominitz JA. Cost effectiveness of testing strategies for chronic hepatitis C. Am J Gastroenterology March 2005; 100 (3): 607-616.

  8. Marín y López RA, Romero ES, Infante RL, Méndez AJ, Berrón RP, Morales AN, Vivar R, Carrada E, Rivera RM; Sánchez GS. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Transfusion 2004; 44: 1344-1349.

  9. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73.

  10. Méndez SN, Uribe EM. Conceptos actuales en Hepatitis C. 2a ed. México: McGraw-Hill, 2005: 85-103.

  11. Aguirre GGE, Martínez AJC, Arenas EIA. Resultados en zona gris del tamizaje para VIH y VHC pueden indicar seroconversión inmediata. Rev Mex Patol Clin 2005; 52 (1): 63-68.

  12. Alter MJ, Kuhmert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recommendations and Reports CDC: February 7, 2003/ 52(RR03): 1-16.

  13. Wenzel RP. Prevention and control of nosocomial infections. 3rd ed. Baltimore: Williams & Wilkins; 1997 p. 1187-1227.

  14. Dufour DR, Talastas M, Fernández MDA, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection. Clin Chem 2003; 49 (3): 479-486.

  15. Tobler LH, Tegtmeier G, Stramer SL, Quan S, Dockter J, Giachetti C, Busch MP. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000; 40: 15-24.

  16. Menitove JE, Richards WA, Destree M. Early US experience with anti-HCV kit in blood donors. Lancet 1990; (336): 244-245.

  17. Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 2004; 44 (3): 349-358.

  18. Polywka S, Schröter M et al. Revelance of reactivity in commercially available hepatitis C virus antibody assays. J Clin Microbiol 2001; 1665-1668.




2020     |     www.medigraphic.com